Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆

•The PURE-01 study tested neoadjuvant pembrolizumab in patients with muscle invasive bladder cancer.•Pembrolizumab has shown promising activity in this setting, reaching 38.5% of complete response (ypT0ypN0).•Event-free survival is also encouraging with 84.5% and 71.7% rates at 12 and 24 months from immunotherapy initiation.•Survival benefit seems spread to all pathological response subgroups with the exception of ypN+ patients.•Molecular...